Pure red cell aplasia following pegylated interferon alpha treatment.
Murat O
MO
Arcasoy
Don C
DC
Rockey
Michael A
MA
Heneghan
D000998:Antiviral Agents / Q000009:adverse effects*; D005260:Female; D006526:Hepatitis C / Q000188:drug therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D016031:Liver Transplantation; D008875:Middle Aged; D011092:Polyethylene Glycols; D011183:Postoperative Complications; D011994:Recombinant Proteins; D012010:Red-Cell Aplasia, Pure / Q000139:chemically induced*
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b